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MicroRNAs are able to control complex programs by 
regulating the expression of hundreds of genes simulta-
neously. Since their discovery almost three decades ago, 
numerous alterations in miRNA expression with varying 
underlying mechanisms were associated with human 
malignancies [1]. Th  e study by Shimono and colleagues 
now shows that certain miRNAs may control the 
molecular makeup of stemness, and may be a shared trait 
of stem cells from various origins: embryonal and adult 
stem cells, normal and malignant stem cells [2]. Th  is 
molecular similarity between normal and malignant stem 
cells re-enforces the concept put forward by the cancer 
stem cell model, according to which stem cells and early 
progenitor cells are more susceptible to transformation 
than their diﬀ  erentiated counterparts [3]. Th  is may be 
due in part to a molecular intracellular context that 
sustains self-renewal and/or high proliferative potential.
Shimono and colleagues performed a comparative 
analysis of puriﬁ  ed  CD44+CD24–lin– cancer stem cell 
populations from three diﬀ  erent breast cancers, which 
revealed diﬀ  erential expression of 37 miRNAs [2]. Among 
these, three clusters of miRNAs were consistently 
downregulated in an additional eight breast cancer 
samples: miRNA-183-96-182, miRNA-200c-141 and 
miRNA-200b-200a-429. Th   e latter two clusters have the 
same seed sequence, suggesting that they may have 
overlapping targets. Remarkably, this downregulation 
appeared to be conserved in embryonal carcinoma cells 
(Tera-2 cells), in normal and malignant mammary stem 
cells of mouse origin deﬁ  ned by the CD24–CD49f+lin–
phenotype [4], and in normal mammary stem/progenitor 
cells deﬁ   ned by the CD49f+EpCAMneg/lowCD31–CD45–
phenotype [5]. When miRNA-200c levels were restored 
in any of these cells, they lost the ability to proliferate in 
vitro, as demonstrated by a dramatic decline in clono-
genicity, and they lost the ability to proliferate in vivo, as 
demonstrated by an inability to generate tumors or 
normal outgrowths upon orthotopic implantation in mice.
In a long list of genes potentially regulated by miRNA-
200c, the authors focused on BMI-1 for further valida-
tion, because of its recognized role in self-renewal. Bmi-1 
is a polycomb group protein that, in a variety of experi-
mental systems, appeared to be necessary for self-
renewal and proliferation of stem cells and appeared able 
to repress diﬀ   erentiation, senes  cence and apoptosis. 
Impres  sively, BMI-1 expression restored the clono   
genicity of MMTV-Wnt 1 breast cancer cells expressing 
miRNA-200c. Th  e MMTV-Wnt 1 cell line was used in 
the study as an experimental model of mouse tumors 
with an expanded stem cell population [4]. Expression of 
miRNA-200c in these cells dramatically reduced clono-
genicity, which was restored to levels seen in uninfected 
cells by lentiviral-driven expression of Bmi-1.
Th  e implications of these ﬁ   ndings are several-fold. 
First, these results suggest the potential use of miRNAs 
as stem cell markers. Fairly simple phenotypes have so far 
been used as stem cell markers, deﬁ  ned by the presence 
of a maximum of 10 to 12 antigens or by the presence of a 
particular cell function, such as transmembrane eﬄ   ux 
(SP population) [6] or enzymatic activity (aldehyde 
dehydro  genase) [7]. Since miRNAs are regulators of large 
molecular programs, they deﬁ   ne much more complex 
phenotypes. Moreover, they appear to confer speciﬁ  c 
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interesting to see whether the upregulation of the miRNA 
clusters miRNA-214, miRNA-127, miRNA-142-3p and 
miRNA-199a, identiﬁ  ed in the same study, is involved in 
promoting stem-cell-speciﬁ   c functions, such as self-
renewal and maintenance of an undiﬀ  erentiated state.
Another potential implication is developing cancer 
therapies by targeting miRNAs, as discussed in the com-
mentary that accompanied Shimono and colleagues’ 
paper [8]. Conceptually identical with cancer therapy 
through diﬀ   erentiation, miRNA targeting puts a 
molecular face to this old notion. By changing the intra-
cellular molecular context, by interfering with the cells’ 
stemness, we may be able to annihilate the consequences 
of cancer-initiating and cancer-promoting events without 
directly targeting them. If clusters of miRNAs with key 
roles in this cell-fate determination are identiﬁ  ed, it may 
be possible to circumvent the challenging task of 
elucidat  ing networks of molecular interactions respon-
sible for cell-fate determination and the complexity 
related to redundancy, feedback regulatory and compen-
satory mechanisms.
What would be the caveats of such approaches? Th  e 
same characteristics that make miRNA appealing targets 
may represent important limitations. As the authors of 
this study mention, the number of miRNAs targets is 
typically large. Moreover, it includes genes that encode 
for molecules with opposing functions. For example, the 
TargetScan analysis of miRNA-200c indicates about 800 
possible targets – some of them, such as Bmi-1, Notch1 
and SOX2, whose upregulation was associated with self-
renewal; and other targets, such as PTEN, whose 
downregulation was associated with an undiﬀ  erentiated 
state and self-renewal [9,10]. Th  is is consistent with 
previous observations that both oncogenes and tumor 
supressors, both genes promoting and suppressing cell 
proliferation, and both proapoptotic and antiapoptotic 
genes can be targets of a certain miRNA [2]. From this 
perspective, the large number of targets may not be advan-
ta  geous when developing miRNA-targeted strategies.
In conclusion, elucidating the role of miRNAs in cell-
fate determination would be an important step for 
understanding the basic biology of stem cells and their 
role during malignant transformation and tumor 
progression. Important applications may be developed 
based on this knowledge, such as using miRNAs as stem 
cell markers. Targeting miRNA also emerges as an 
opportunistic shortcut to circumvent the complexity 
resulting from feedback regulatory and compensatory 
mechanisms when aiming to eﬀ  ectively change cellular 
programs that dictate cell fate. Developing therapeutic 
approaches based on this concept should be considered 
with extreme caution, however, given the considerable 
potential for side eﬀ  ects.
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